About Contact Us Careers

Topical Androgen Receptor Inhibitors Market Size and Forecast, by Indication (Androgenetic Alopecia, Hirsutism); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 5828
  • Published Date: Nov 28, 2025
  • Report Format: PDF, PPT

Topical Androgen Receptor Inhibitors Market Outlook:

Topical Androgen Receptor Inhibitors Market size was over USD 58.45 million in 2025 and is anticipated to cross USD 242.7 million by 2035, growing at more than 15.3% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of topical androgen receptor inhibitors is assessed at USD 66.5 million.

Topical Androgen Receptor Inhibitors Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The need for potent topical androgen receptor inhibitors is driven by the increasing incidence of androgenetic alopecia and hirsutism, two disorders associated with androgen receptors. AGA is becoming more commonplace worldwide because of a combination of lifestyle, hormone fluctuations, and genetics. A greater number of patients are seeking effective treatments, such as topical androgen receptor inhibitors, as a result of this rising incidence. Excessive hair growth in women, frequently with a male pattern, is a symptom of hirsutism. Hormonal imbalances and conditions such as polycystic ovarian syndrome (PCOS) can aggravate hirsutism. Data from the World Health Organization (WHO) in June 2023 indicate that 8–13% of women of reproductive age have PCOS. Worldwide, up to 70% of afflicted women go undetected.

People are looking for ways to control their undesired hair growth as awareness of these conditions increases, which is driving up demand for topical androgen receptor inhibitors. The increasing prevalence of androgen-related conditions is a significant growth factor for the topical androgen receptor inhibitors market.

Key Topical Androgen Receptor Inhibitors Market Insights Summary:

  • Regional Highlights:

    • By 2035, North America is projected to command a 34% share of the topical androgen receptor inhibitors market, expanding primarily owing to the escalating demand for aesthetic and cosmetic procedures.
    • Asia Pacific is expected to secure a 22% share by 2035, with market momentum strengthened as a consequence of increasing PCOS prevalence and rising adoption of cosmetic hair-removal treatments.

  • Segment Insights:

    • The androgenetic alopecia segment in the topical androgen receptor inhibitors market is anticipated to capture a 55% share during 2026-2035, underpinned by surging awareness of AGA treatments and the shift toward personalized, non-invasive therapeutic options.
    • The hospital pharmacy segment is forecasted to account for a 47% share by 2035, supported as patients increasingly rely on professional oversight and prescription-based access to topical androgen receptor inhibitors.

  • Key Growth Trends:

    • Growing Aging Population
    • Rising Awareness and Adoption of Cosmetic Solutions

  • Major Challenges:

    • High Cost of Topical Androgen Receptor Inhibitors
    • Availability of Alternative Treatments may Hinder the Growth of the Market

  • Key Players: Cosmo Pharmaceuticals, Suzhou Kintor Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Aranda Pharma Ltd, Selleck Chemicals, Astellas Pharma, Takeda Pharmaceutical, and Daiichi Sankyo.

Global Topical Androgen Receptor Inhibitors Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 58.45 million
    • 2026 Market Size: USD 66.5 million
    • Projected Market Size: USD 242.7 million by 2035
    • Growth Forecasts: 15.3%

  • Key Regional Dynamics:

    • Largest Region: North America (34% Share by 2035)
    • Fastest Growing Region: Asia Pacific
    • Dominating Countries: United States, China, Japan, Germany, South Korea
    • Emerging Countries: India, Brazil, Australia, United Kingdom, Canada

    • Last updated on : 28 November, 2025

Growth Drivers

  • Growing Aging Population: According to the WHO, one in six persons on the globe will be 60 years of age or older by 2030. The number of individuals in the world who are 60 years of age or older is expected to double (to 2.1 billion) by 2050. Hormonal imbalances, particularly variations in androgen levels, can be brought on by aging. AGA and hirsutism are two androgen-related disorders that are exacerbated by these abnormalities. Male-pattern baldness, also known as androgenetic alopecia, is a disorder that is frequently linked to aging. Hormonal changes, especially those related to androgen levels, can exacerbate hair loss in older people. Since topical androgen receptor inhibitors (TARIs) are intended to control androgen activity, they are relevant for treating conditions more common in the aging population. Therefore, the growing aging population is a substantial growth factor for the topical androgen receptor inhibitors market.
  • Rising Awareness and Adoption of Cosmetic Solutions: Concerns about appearance, particularly those about hair loss, are frequently more pressing as people age. Age-related concerns about appearance are becoming increasingly widely accepted, and older people are generally better aware of the cosmetic options that are accessible. The topical androgen receptor inhibitors market  is influenced by this acceptance and awareness.
  • Growing Healthcare Spending: According to the data provided by World Health Organization; Global health spending hit US$9 trillion in 2020. New topical androgen receptor inhibitor clinical studies can more easily be started when there is sufficient financing for healthcare. Obtaining regulatory permissions and carrying out clinical trials might come at a significant expense. These procedures are made possible by more healthcare spending, which enables pharmaceutical companies to launch more advanced and novel drugs. Spending on healthcare helps to increase topical androgen receptor inhibitors market access and distribution networks, among other aspects of infrastructure. This is essential to guarantee that patients and healthcare professionals have widespread access to topical androgen receptor inhibitors. Pharmaceutical items can be distributed and made accessible more efficiently with the support of a well-established healthcare infrastructure.

Challenges

  • High Cost of Topical Androgen Receptor Inhibitors: For some patient populations, the high cost of topical androgen receptor inhibitors may prevent them from being prescribed. Market penetration may be restricted as a result of a smaller group of people who can afford or are prepared to invest in these treatments due to affordability problems. The price of topical androgen receptor inhibitors may have an impact on patients' compliance with prescribed treatment plans. Patients may be less inclined to regularly take the medication as directed if they believe the treatment is too costly, which could have an adverse effect on overall market growth and result in unfavorable outcomes.
  • Limited Efficacy in Severe Cases may Hinder the Growth of the topical androgen receptor inhibitors market
  • Availability of Alternative Treatments may Hinder the Growth of the Market.

Topical Androgen Receptor Inhibitors Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2026-2035

CAGR

15.3%

Base Year Market Size (2025)

USD 58.45 million

Forecast Year Market Size (2035)

USD 242.7 million

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Topical Androgen Receptor Inhibitors Market Segmentation:

Indication Segment Analysis

The Androgenetic alopecia segment in the topical androgen receptor inhibitors market is anticipated to hold a share of 55% during the forecast period. Several factors affect the growth of Topical Androgen Receptor Inhibitors (TARI) in the Androgenetic Alopecia (AGA) segment. People are looking for effective remedies, like TARI, as a result of growing awareness of AGA treatments that are available, as well as rising concerns about appearance and the desire to seem younger. Personalized medicine and patient-centered healthcare are popular trends that support the creation of individualized treatment plans. TARI fits in with this patient-centered strategy as a targeted treatment for AGA. Additionally, people now have localized, non-invasive therapy alternatives due to the development and marketing of topical formulations like Clascoterone that can block androgen receptors. The  market in the AGA segment is expanding as a result of all these elements.

Distribution Channel Segment Analysis

The hospital pharmacy segment in the topical androgen receptor inhibitors market is anticipated to hold a share of 47% by the end of 2035. Patients seeking topical androgen receptor inhibitors can benefit from the clinical experience and supervision of pharmacists and dermatologists, who are frequently available in hospital pharmacies. The availability of expert guidance boosts patients' trust in the efficiency and appropriate administration of these drugs. Prescription drugs frequently contain tartrogen receptor inhibitors. To guarantee that patients receive the recommended dosage and formulation, hospital pharmacies are essential in the distribution of prescription pharmaceuticals. Given these factors, it is projected that this segment's market will expand.

Our in-depth analysis of the global market includes the following segments:

          Indication
  • Androgenetic Alopecia
  • Hirsutism

          Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Topical Androgen Receptor Inhibitors Market - Regional Analysis

North American Market Insights

North America industry is estimated to hold largest revenue share of 34% by 2035. This is mostly because there aren't many resources available in the region and the demand for cosmetic operations is rising. The main cause was the rising use of aesthetic procedures in the region to improve the appearance of both adult and senior citizens. Male pattern baldness and unwanted hair growth are two cosmetic concerns that are driving up demand for solutions that address them since looks and aesthetics are becoming more and more important in society. It is therefore expected that the market in the North American region will expand.

APAC Market Insights

Asia Pacific topical androgen receptor inhibitors market is poised to hold the second largest share of 22% during the forecast period. In the coming years, there will likely be significant growth in the Asia-Pacific region. This is a result of an increase in PCOS and hirsutism cases as well as cosmetic operations performed by more people to remove excessive body hair. In the Asia-Pacific, South Korea, China, Japan, and India are the largest markets. This is mostly due to the high diagnostic rates and widespread awareness of laser hair removal procedures in these nations. Another factor contributing to the growth of this market in the Asia-Pacific region is the fact that Japan has the highest number of laser hair removal operations performed worldwide. PCOS, or polycystic ovarian syndrome, is increasingly frequent in women and can cause hirsutism. This is the primary factor propelling the topical androgen receptor inhibitors market in this region.

Topical Androgen Receptor Inhibitors Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Topical Androgen Receptor Inhibitors Market Players:

    • Cosmo Pharmaceuticals
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Suzhou Kintor Pharmaceuticals Inc
    • Sun Pharmaceutical Industries Limited
    • Aranda Pharma Ltd
    • Selleck Chemicals

Recent Developments

  • Aug 2020- The U.S. FDA has approved the first-in-class androgen receptor inhibitor, carotene cream 1% (Winlevi, Cassiopea), for the treatment of acne vulgaris in individuals 12 years of age and older.
  • Apr 2021- The National Medical Products Administration has given the green light for Kintor Pharmaceutical, a clinical-stage biotechnology company developing novel small molecule and biological therapeutics, to start GT20029 (gel/tincture) clinical trials for the treatment of androgenetic alopecia and acne.
  • Nov 2023- The supplemental new drug application for XTANDI® has been approved by the U.S. Food and Drug Administration (FDA), as announced by Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. With this approval, XTANDI turns out the first and only androgen receptor signaling inhibitor authorized by the FDA for the management of patients with biochemically driven recurrence of nonmetastatic castration-sensitive prostate cancer (nmCSPC) who are at high risk of developing metastatic disease.
  • Report ID: 5828
  • Published Date: Nov 28, 2025
  • Report Format: PDF, PPT
  • Explore a preview of key market trends and insights
  • Review sample data tables and segment breakdowns
  • Experience the quality of our visual data representations
  • Evaluate our report structure and research methodology
  • Get a glimpse of competitive landscape analysis
  • Understand how regional forecasts are presented
  • Assess the depth of company profiling and benchmarking
  • Preview how actionable insights can support your strategy

Explore real data and analysis

Download Free Sample Report

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of topical androgen receptor inhibitors is assessed at USD 66.5 million.

The global topical androgen receptor inhibitors market size was valued at around USD 58.45 million in 2025 and is projected to grow at a CAGR of more than 15.3%, reaching USD 242.7 million revenue by 2035.

By 2035, North America is projected to command a 34% share of the topical androgen receptor inhibitors market, expanding primarily owing to the escalating demand for aesthetic and cosmetic procedures.

Key players in the market include Cosmo Pharmaceuticals, Suzhou Kintor Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Aranda Pharma Ltd, Selleck Chemicals, Astellas Pharma, Takeda Pharmaceutical, and Daiichi Sankyo.

Topical Androgen Receptor Inhibitors Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos